The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Association Between Use of β-Blockers and Outcomes in Patients With Heart Failure and Preserved Ejection Fraction
Abstract
IMPORTANCE: Heart failure with preserved ejection fraction (HFPEF) may be as common and may have similar mortality as heart failure with reduced ejection fraction (HFREF). β-Blockers reduce mortality in HFREF but are inadequately studied in HFPEF. OBJECTIVE: To test the hypothesis that β-blockers are associated with reduced all-cause mortality in HFPEF. DESIGN: Propensity score-matched cohort study using the Swedish Heart Failure Registry. Propensity scores for β-blocker use were derived from 52 baseline clinical and socioeconomic variables. SETTING: Nationwide registry of 67 hospitals with inpatient and outpatient units and 95 outpatient primary care clinics in Sweden with patients entered into the registry between July 1, 2005, and December 30, 2012, and followed up until December 31, 2012. PARTICIPANTS: From a consecutive sample of 41,976 patients, 19,083 patients with HFPEF (mean [SD] age, 76 [12] years; 46% women). Of these, 8244 were matched 2:1 based on age and propensity score for β-blocker use, yielding 5496 treated and 2748 untreated patients with HFPEF. Also we conducted a positive-control consistency analysis involving 22,893 patients with HFREF, of whom 6081 were matched yielding 4054 treated and 2027 untreated patients. EXPOSURES: β-Blockers prescribed at discharge from the hospital or during an outpatient visit, analyzed 2 ways: without consideration of crossover and per-protocol analysis with censoring at crossover, if applicable. MAIN OUTCOMES AND MEASURES: The prespecified primary outcome was all-cause mortality and the secondary outcome was combined all-cause mortality or heart failure hospitalization. RESULTS: Median follow-up in HFPEF was 755 days, overall; 709 days in the matched cohort; no patients were lost to follow-up. In the matched HFPEF cohort, 1-year survival was 80% vs 79% for treated vs untreated patients, and 5-year survival was 45% vs 42%, with 2279 (41%) vs 1244 (45%) total deaths and 177 vs 191 deaths per 1000 patient-years (hazard ratio [HR], 0.93; 95% CI, 0.86-0.996; P = .04). β-Blockers were not associated with reduced combined mortality or heart failure hospitalizations: 3368 (61%) vs 1753 (64%) total for first events, with 371 vs 378 first events per 1000 patient-years (HR, 0.98; 95% CI, 0.92-1.04; P = .46). In the matched HFREF cohort, β-blockers were associated with reduced mortality (HR, 0.89; 95% CI, 0.82-0.97, P=.005) and also with reduced combined mortality or heart failure hospitalization (HR, 0.89; 95% CI, 0.84-0.95; P = .001). CONCLUSIONS AND RELEVANCE: In patients with HFPEF, use of β-blockers was associated with lower all-cause mortality but not with combined all-cause mortality or heart failure hospitalization. β-Blockers in HFPEF should be examined in a large randomized clinical trial.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2013 ACCF/AHA Guideline for the Management of Heart Failure
Yancy, C. W., Jessup, M., Bozkurt, B., Butler, J., Casey, D. E., Drazner, M. H., Fonarow, G. C., Geraci, S. A., Horwich, T., Januzzi, J. L., et al. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.05.019 · Cited by 12,536
External review and validation of the Swedish national inpatient register
Ludvigsson, J. F., Andersson, E., Ekbom, A., Feychting, M., Kim, J.-L., Reuterwall, C., Heurgren, M., & Olausson, P. O. (2011) · BMC Public Health · doi:10.1186/1471-2458-11-450 · Cited by 5,055
Kitzman, D. W. (2002) · JAMA · doi:10.1001/jama.288.17.2144 · Cited by 883
β-Blockers in Congestive Heart Failure: A Bayesian Meta-Analysis
Brophy, J. M., Joseph, L., & Rouleau, J. L. (2001) · Annals of Internal Medicine · doi:10.7326/0003-4819-134-7-200104030-00008 · Cited by 389
Cited by
Global Public Health Burden of Heart Failure
Savarese, G., Lund, L. H., Division of Cardiology, D. O. M., Department of Cardiology, K. U. H., Division of Cardiology, D. O. M., & Department of Cardiology, K. U. H. (2017) · Cardiac Failure Review · doi:10.15420/cfr.2016:25:2 · Cited by 2,641
Self-citationTsutsui, H., Isobe, M., Ito, H., Ito, H., Okumura, K., Ono, M., Kitakaze, M., Kinugawa, K., Kihara, Y., Goto, Y., et al. (2019) · Circulation Journal · doi:10.1253/circj.cj-19-0342 · Cited by 704
Heart failure with mid-range or mildly reduced ejection fraction
Savarese, G., Stolfo, D., Sinagra, G., & Lund, L. H. (2022) · Nature Reviews Cardiology · doi:10.1038/s41569-021-00605-5 · Cited by 476
Self-citationGorter, T. M., van Veldhuisen, D. J., Bauersachs, J., Borlaug, B. A., Celutkiene, J., Coats, A. J. S., Crespo-Leiro, M. G., Guazzi, M., Harjola, V.-P., Heymans, S., et al. (2018) · European Journal of Heart Failure · doi:10.1002/ejhf.1029 · Cited by 389
Self-citationA Comprehensive Population-Based Characterization of Heart Failure with Mid-Range Ejection Fraction
Koh, A. S., Tay, W. T., Teng, T. H. K., Vedin, O., Benson, L., Dahlstrom, U., Savarese, G., Lam, C. S. P., & Lund, L. H. (2017) · European Journal of Heart Failure · doi:10.1002/ejhf.945 · Cited by 316
Self-citation
Metadata
- Authors
- Lund, L. H., Benson, L., Dahlström, U., Edner, M., & Friberg, L.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2014-11-19
- Volume
- 312
- Issue
- 19
- Pages
- 2008
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W2161149683
- Cited by
- 174
- References
- 4
- FWCI
- 12.42
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Association Between Use of β-Blockers and Outcomes in Patients With Heart Failure and Preserved Ejection Fraction. https://app.cochat.ai/papers/10.1001/jama.2014.15241
- The paper
- Lund, L. H., Benson, L., Dahlström, U., Edner, M., & Friberg, L. (2014). Association Between Use of β-Blockers and Outcomes in Patients With Heart Failure and Preserved Ejection Fraction. JAMA. https://doi.org/10.1001/jama.2014.15241
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.